AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win Read More »
